Initial monoamine oxidase-A inhibition by moclobemide does not predict the therapeutic response in patients with major depression

[1]  A. Puech,et al.  Monoamine oxidase A and B activities in heavy smokers , 1995, Biological Psychiatry.

[2]  A. Patat,et al.  Pressor Effect of Oral Tyramine During Treatment with Befloxatone, a New Reversible Monoamine Oxidase‐A Inhibitor, in Healthy Subjects , 1995, Journal of clinical pharmacology.

[3]  D. Goldstein,et al.  The neuronal and extraneuronal origins of plasma 3-methoxy-4-hydroxyphenylglycol in rats. , 1994, Journal of the autonomic nervous system.

[4]  D. Goldstein,et al.  Chronic inhibition of monoamine oxidase type A increases noradrenaline release in rat frontal cortex , 1993, Naunyn-Schmiedeberg's Archives of Pharmacology.

[5]  T. Hergueta,et al.  Comparison of the monoamine oxidase inhibiting properties of two reversible and selective monoamine oxidase-A inhibitors moclobemide and toloxatone, and assessment of their effect on psychometric performance in healthy subjects. , 1990, British journal of clinical pharmacology.

[6]  J. Guelfi,et al.  Efficacy of reversible inhibitors of monoamine oxidase‐A in various forms of depression , 1990, Acta psychiatrica Scandinavica. Supplementum.

[7]  P. Janicak,et al.  MAO inhibition and clinical response in depressed patients treated with phenelzine. , 1990, The Journal of clinical psychiatry.

[8]  D. Goldstein,et al.  Plasma dihydroxyphenylalanine and total body and regional noradrenergic activity in humans. , 1989, The Journal of clinical endocrinology and metabolism.

[9]  M. Koulu,et al.  Inhibition of monoamine oxidase by moclobemide: effects on monoamine metabolism and secretion of anterior pituitary hormones and cortisol in healthy volunteers. , 1989, British journal of clinical pharmacology.

[10]  D. Goldstein,et al.  Source and physiological significance of plasma 3,4-dihydroxyphenylglycol and 3-methoxy-4-hydroxyphenylglycol. , 1988, Journal of the autonomic nervous system.

[11]  W. Maier,et al.  Reliability and validity of the Newcastle Scales in relation to ICD‐9‐classification , 1987, Acta psychiatrica Scandinavica.

[12]  J. Hsiao,et al.  The effects of antidepressants on the cerebrospinal fluid homovanillic acid/5‐hydroxyindoleacetic acid ratio , 1987, Clinical pharmacology and therapeutics.

[13]  D. Murphy,et al.  Simultaneous liquid-chromatographic determination of 3,4-dihydroxyphenylglycol, catecholamines, and 3,4-dihydroxyphenylalanine in plasma, and their responses to inhibition of monoamine oxidase. , 1986, Clinical chemistry.

[14]  I. Kopin,et al.  Catecholamine metabolism: basic aspects and clinical significance. , 1985, Pharmacological reviews.

[15]  M. Åsberg,et al.  A New Depression Scale Designed to be Sensitive to Change , 1979, British Journal of Psychiatry.

[16]  J. Davidson,et al.  Inhibition of platelet monoamine oxidase in depressed subjects treated with phenelzine. , 1978, The American journal of psychiatry.

[17]  K. Lamborn,et al.  A multiple-dose, controlled study of phenelzine in depression-anxiety states. , 1976, Archives of general psychiatry.

[18]  W. Burkard,et al.  Biochemistry and pharmacology of moclobemide, a prototype RIMA , 2005, Psychopharmacology.

[19]  A. Korn,et al.  Biochemical effects of high single doses of moclobemide in man: correlation with plasma concentrations , 2005, Psychopharmacology.

[20]  P. Riederer,et al.  Plasma moclobemide and metabolites: lack of correlation with clinical response and biogenic amines , 2004, Psychopharmacology.

[21]  M. Youdim,et al.  The role of monoamine oxidase A in the metabolism and function of noradrenaline and serotonin , 1984 .